OBJECTIVES: This study used a stated preference discrete choice experiment (DCE) to explore the preferences and willingness to pay (WTP) of RR-MS patients in the UK regarding the benefits of treatments. METHODS: The attributes in the DCE included the number of future relapses, presence of new nerve damage, progression in disability level and out of pocket cost (to estimate WTP for changes in attribute levels). Participants were asked to indicate their preference for hypothetical treatment profiles that varied attribute levels based on an orthogonal fold-over design. The patient sample (n=194) was recruited through advertisement with a patient advocacy group. WTP was estimated using logit analysis. RESULTS: Eighty-three percent of patients (mean age 44 years, 82% female) had experienced 1 or more relapses in the last 2 years and 46% required aid with ambulation. Patients had a mean annual household income of £33,000 and monthly MS-related expenditures of approximately £50. The estimated monthly WTP for a combined benefit of no disability progression, new nerve damage or relapses was approximately 9 times their current expenditures and 16% of their mean annual income. The most highly valued treatment outcome was avoidance of disability progression in the next year. Segmented analyses indicated that patients not currently experiencing a relapse and those with lower self-reported levels of disability had higher WTP for improvements in the other treatment benefit attributes. CONCLUSION: RR-MS patients indicated a differential demand for avoidance of MS related disability progression, relapses and nerve damage. Patients who were less severely affected by their RR-MS were willing to pay more to reduce the burden of their disease. This study underlines the high value patients place on the avoidance of MS sequelae, particularly disability progression.